Funding will support clinical development of EPF-001, a first-in-class G9a inhibitor for sickle cell disease and beta thalassemia Company built on pioneering research from RIKEN and Tokyo University ...
Please provide your email address to receive an email when new articles are posted on . Researchers at Boston Medical Center identified a new small molecule that could benefit people with sickle cell ...
The targeted protein degrader BMS-986470 from Bristol Myers Squibb (BMS) boosts levels of fetal hemoglobin in cells, mice, and monkeys, the company reported this weekend at the American Society of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results